Cardiff OncologyNASDAQ: CRDF

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.

Cardiff Oncology, Inc. (NASDAQ: CRDF) Q1 2024 Results Earnings Conference Call will take place on May 2, 2024 at 4:30 PM ET. The call will be led by Kiki Patel from Investor Relations at Gilmartin Group, with Mark Erlander as CEO and Jamie Levine as CFO. Conference Call Participants include Mark Frahm from TD Cowen, Joseph Catanzaro from Piper Sandler, and Andy Hsieh from William Blair. Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. All participants are currently in a listen-only mode.

Cardiff Oncology (CRDF) reported a quarterly loss of $0.22 per share, which was better than the expected loss of $0.25 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.25 per share in the same quarter last year.

Management will host a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT.

Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Cardiff Oncology (CRDF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial.